Hypertension

Validic to distribute Withings cellular devices

Retrieved on: 
Tuesday, February 27, 2024
Diabetes, Heart, Quality of life, EHR, Sale, Wi-Fi, Hypertension, Patient, Health equity

DURHAM, N.C., Feb. 27, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, and Withings Health Solutions, a global leader of innovative and patient-centric connected devices, have signed an agreement for the sale and distribution of Withings cellular devices through Validic's subsidiary, Validic Logistics LLC.

Key Points: 
  • DURHAM, N.C., Feb. 27, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, and Withings Health Solutions, a global leader of innovative and patient-centric connected devices, have signed an agreement for the sale and distribution of Withings cellular devices through Validic's subsidiary, Validic Logistics LLC.
  • Validic Logistics will sell and distribute the Withings Body Pro, a cellular smart scale, and Withings BPM Connect Pro, a cellular blood pressure monitor to health systems and healthcare providers using connected health devices to remotely monitor patients with chronic health conditions like hypertension, diabetes, and congestive heart failure.
  • The addition of the Withings cellular and smart devices expands the availability and breadth of devices offered to support patients enrolled in remote monitoring and chronic condition management programs.
  • "We are pleased to expand our relationship with Withings Health Solutions, who has been a partner since 2013, by becoming an official distributor of Withings smart devices," said Validic CEO and Co-founder Drew Schiller.

"Huddle for Health Challenge" Launches, Spearheaded by NFL Alumni Association and ScaleHealth in Alliance with CHIME at the ViVE Event

Retrieved on: 
Tuesday, February 27, 2024
Diabetes, College, CHIME, National Football League Alumni, Quality of life, Sport, Health, Hypertension, Organization, ViVe, Movement, NFL, Partnership

This partnership with ScaleHealth and the NFL Alumni Association embodies our collective commitment to addressing our communities' health challenges today."

Key Points: 
  • This partnership with ScaleHealth and the NFL Alumni Association embodies our collective commitment to addressing our communities' health challenges today."
  • "As NFL Alumni and beacons of our community, we have a special opportunity to make long-lasting and positive impacts to improve health and wellness from which we reside, "said Kyle Richardson, Managing Member of NFL Alumni Health.
  • The initiative aims to spark significant change across the health and wellness landscape by uniting healthcare leaders and tech innovators.
  • Stay tuned for more details about the initiative, and join us in this transformative journey by visiting www.nflalumnihealth.org/VIVE-2024 .

Aktiia Secures CHF 27 Million (USD 30M) in Funding from Khosla Ventures and Others, Welcomes Daniel Graf as New President and Board Member to Accelerate Innovation in Hypertension Management

Retrieved on: 
Tuesday, February 27, 2024
Blood pressure, USD, Entrepreneurship, Uber, Heart rate, Daniel, CHF, Verve, Death, Data, Khosla Ventures, Hypertension, Health, Deep learning, Research, Pharmaceutical industry

In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.

Key Points: 
  • In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.
  • Daniel, a seasoned technology executive with a distinguished career at companies like Uber and Google, brings a wealth of experience in entrepreneurship, product innovation, and scaling businesses.
  • His leadership will be instrumental in guiding Aktiia's strategic direction and expansion as the company continues to pioneer advancements in hypertension management.
  • "We are proud to have Daniel join our board and executive team," said Mattia Bertschi, CEO of Aktiia.

Aktiia Secures CHF 27 Million (USD 30M) in Funding from Khosla Ventures and Others, Welcomes Daniel Graf as New President and Board Member to Accelerate Innovation in Hypertension Management

Retrieved on: 
Tuesday, February 27, 2024
Blood pressure, USD, Entrepreneurship, Uber, Heart rate, Daniel, CHF, Verve, Death, Data, Khosla Ventures, Hypertension, Health, Deep learning, Research, Pharmaceutical industry

In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.

Key Points: 
  • In conjunction with this funding, Aktiia is delighted to welcome Daniel Graf as its new President and Board Member.
  • Daniel, a seasoned technology executive with a distinguished career at companies like Uber and Google, brings a wealth of experience in entrepreneurship, product innovation, and scaling businesses.
  • His leadership will be instrumental in guiding Aktiia's strategic direction and expansion as the company continues to pioneer advancements in hypertension management.
  • "We are proud to have Daniel join our board and executive team," said Mattia Bertschi, CEO of Aktiia.

Validic integrates Smart Meter cellular-enabled health devices into personalized care platform

Retrieved on: 
Monday, February 26, 2024
Diabetes, Metre, FDA, Vital signs, Literacy, Health, COVID-19, Hypertension, ViVe, Patient, Health equity, COPD, Smart meter, Mobile phone

DURHAM, N.C., Feb. 26, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, continues to expand its personalized care solution with the integration of Smart Meter cellular devices.

Key Points: 
  • DURHAM, N.C., Feb. 26, 2024 /PRNewswire/ -- Validic Inc., a market-leading digital health and personalized care company, continues to expand its personalized care solution with the integration of Smart Meter cellular devices.
  • The addition of Smart Meter cellular-enabled home health devices brings an added layer of health equity into the Validic platform by lowering technology literacy barriers.
  • "The addition of Smart Meter cellular-enabled health monitoring devices to our platform offers another option to help people, particularly those challenged with serious chronic health conditions, focus on improving health and living their best lives."
  • For more information about using Smart Meter cellular-enabled connected health devices with your Validic-powered health programs, submit a request to [email protected] .

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
Thursday, February 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation

Retrieved on: 
Thursday, February 22, 2024
Esophagitis, Tricuspid valve, Denervation, General partnership, Mitral regurgitation, Johnson & Johnson, Mayo Clinic, Clinical professor, Hypertension, Ethicon, Mitral valve, Patient, Disease, Pharmaceutical industry

MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.

Key Points: 
  • MINNEAPOLIS, Feb. 22, 2024 /PRNewswire/ --  NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment of mitral valve regurgitation.
  • The company appointed Todd Berg as Chief Executive Officer to oversee clinical and commercial programs for transeptal and transapical repair of damaged mitral valve chords resulting in regurgitation.
  • Berg has over 30 years of experience successfully developing and commercializing novel medical therapies and holds over 100 U.S. patents.
  • The opportunity to develop a first-line therapy for mitral valve disease, by resolving regurgitation early in the disease state, is incredibly compelling," said Berg.

Ciba Health Taps Instacart to Help Enable Improved Access to Nutritious Foods Through Chronic Disease Care Platform

Retrieved on: 
Thursday, February 22, 2024
Philosophy, Physician, Obesity, Food, Health, Hypertension, DSM-IV codes, Organization, Patient, Medicine, Instacart, Pharmaceutical industry

Ciba Health's approach involves providing patients with access to multidisciplinary care teams comprising physicians, dietitians, and health coaches.

Key Points: 
  • Ciba Health's approach involves providing patients with access to multidisciplinary care teams comprising physicians, dietitians, and health coaches.
  • "As leaders in our respective fields, Ciba Health is proud to integrate with Instacart to help address a critical aspect of healthcare – nutrition.
  • "Access to nutritious foods can play a vital role in ensuring the health and wellness of our communities," said Sarah Mastrorocco, Vice President and General Manager of Instacart Health.
  • Using Instacart Health technology, Ciba Health will set new standards for healthcare and nutrition integration, ultimately contributing to the well-being of individuals and communities.

HealthSnap Closes $25 Million Series B Funding Amidst Continued Triple Digit Growth of Remote Patient Monitoring and Chronic Care Management Platform

Retrieved on: 
Wednesday, February 21, 2024
Senior, CCM, RPM, American Heart Association, Investment, Obesity, Chronic care management, Growth, Prisma Health, Venture capital, Heart failure, Type 2 diabetes, Type 2, Hypertension, Remote patient monitoring, UnityPoint Health, Patient, Comcast Ventures, Partnership, Nursing

MIAMI, Feb. 21, 2024 /PRNewswire/ -- HealthSnap, a Miami-based Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution for healthcare providers, today announced its Series B financing totaling $25 million. The round was led by Sands Capital, with new investments from Comcast Ventures, Acronym Venture Capital, and Florida Opportunity Fund. Existing shareholders, Asclepius Growth Capital, Florida Funders, MacDonald Ventures, and TGH Ventures also participated in the round. Scott Frederick, a Managing Partner at Sands Capital, will join HealthSnap's board of directors.

Key Points: 
  • MIAMI, Feb. 21, 2024 /PRNewswire/ -- HealthSnap , a Miami-based Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) solution for healthcare providers, today announced its Series B financing totaling $25 million.
  • Existing shareholders, Asclepius Growth Capital, Florida Funders, MacDonald Ventures, and TGH Ventures also participated in the round.
  • In the last 18 months, HealthSnap has grown exponentially, bolstered by the successful expansion of its market-leading Remote Patient Monitoring (RPM) platform with the addition of a comprehensive Chronic Care Management (CCM) solution.
  • HealthSnap is actively hiring for care navigator nurse positions, customer success managers, and patient enrollment specialists.

Dr. Jose Villar Wins 2024 March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition

Retrieved on: 
Tuesday, February 20, 2024
Woman, Body composition, Microcephaly, Diet, Randomized controlled trial, Pregnancy, Obesity, Growth, Fetus, PAS, Life, Stanford University, Health, University, Mother, World Health Organization, Hypertension, Medicine, Infant, Pre-eclampsia, University of Oxford, Breast milk, CDC, Preterm birth, WHO, Research, Dietary supplement

ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition. Dr. Villar, a Professor of Perinatal Medicine at Oxford's Nuffield Department of Women's and Reproductive Health and the former Coordinator of Maternal and Perinatal Health at the World Health Organization (WHO) has spent more than a half century researching the effect of maternal nutrition on the health, growth, and development of babies. The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.

Key Points: 
  • Prominent Oxford scientist led studies on fetal growth, newborn size, and preterm postnatal growth
    ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition.
  • The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.
  • They present a universal blueprint for healthy growth and development from early gestation to two years of age.
  • That is the challenge ahead, and I couldn't be prouder to continue it alongside March of Dimes."